Roche’s Blood Disorder Drug Crovalimab Takes Step Toward FDA Approval

By Cecilia Butini

Roche said Wednesday that the U.S. Food and Drug Administration has accepted its application for monoclonal antibody crovalimab for the treatment of rare blood condition paroxysmal nocturnal hemoglobinuria.

The government agency has accepted Roche’s Biologics License Application, which is required to introduce a biologic…